Cointime

Synthekine

company

About

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

  • 11 - 50

Highlights

Total Funding Amount
$107.50M
Funding Rounds
1
Investors
1
Investments
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$107.50M
Industries
Biotechnology,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$107.50M
Synthekine has raised a total of $107.50M in funding over 2 rounds. Their latest funding was raised on Jun 10, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 10, 2021 Series B $107.50M 1 — — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Synthekine has made 1 investments. Their most recent investment was on Feb 17, 2021, when Artie raised $11M.
Date Company Name
Round Money Raised Industry Lead Investor
Feb 17, 2021 Artie
Seed $11M Blockchain —

Investors

Number of Lead Investors
Number of Investors
—
1
Synthekine is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures — Series B
Cointime
เนื้อหา
บริษัท